| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 35,600 | 35,800 | 21.03. | |
| 35,200 | 36,200 | 20.03. |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin | Patent strengthens global intellectual property protection for QTORIN rapamycin, Palvella's lead product candidate from the QTORIN platform, in development for serious, rare skin diseases and vascular... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations | Primary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint (p 95% of trial participants aged... ► Artikel lesen |
| Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |